Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases
- PMID: 11477574
- DOI: 10.1002/ijc.1381
Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases
Abstract
Carcinoma cell lines are frequently refractory to transforming growth factor-beta (TGF beta)-mediated cell cycle arrest. Whether and how TGF beta signaling is disrupted in the majority of human tumors, however, remains unclear. To investigate whether TGF beta signaling might be disrupted by inactivation of the key signaling molecule, the TGF beta type I (T beta R-I) receptor, and whether or not T beta R-I inactivation is associated with late stage disease, we conducted a comprehensive structural analysis of the T beta R-I gene in fine-needle aspirates of 23 head-&-neck cancer metastases. We encountered 4 different mutations of T beta R-I, 3 of which have not been previously identified. In 1 case, we found a somatic intragenic 4-bp deletion predicting for a truncation of the receptor protein. This is the first example of a true loss-of-function mutation of T beta R-I in a human epithelial neoplasm. In 2 other cases, we identified missense mutations located between the juxtamembrane- and serine-threonine kinase domains. One of these resulted in an alanine-to-threonine substitution (A230T), which disrupts receptor signaling activity by causing rapid protein degradation within the endoplasmatic reticulum. This represents a novel mechanism of inactivation of a TGF beta signaling intermediate. Finally, we identified a serine-to-tyrosine substitution at codon 387 (S387Y) in a metastasis but not in the corresponding primary tumor. We had previously shown this S387Y mutant to be predominantly associated with breast cancer metastases and to have a diminished ability to mediate TGF beta-dependent signaling. In aggregate, these findings provide further support for the hypothesis that inactivation of the TGF beta signaling pathway occurs in a significant subset of human cancers.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity.EMBO J. 1997 Jul 1;16(13):3912-23. doi: 10.1093/emboj/16.13.3912. EMBO J. 1997. PMID: 9233801 Free PMC article.
-
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.Cancer Lett. 2007 Jan 8;245(1-2):163-70. doi: 10.1016/j.canlet.2006.01.003. Epub 2006 Feb 14. Cancer Lett. 2007. PMID: 16478646 Free PMC article.
-
Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of transforming growth factor-beta.J Biol Chem. 1996 Feb 2;271(5):2769-75. doi: 10.1074/jbc.271.5.2769. J Biol Chem. 1996. PMID: 8576253
-
Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis.Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68. doi: 10.1016/s1359-6101(99)00039-8. Cytokine Growth Factor Rev. 2000. PMID: 10708963 Review.
-
TGF-betas and TGF-beta receptors in atherosclerosis.Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):103-14. doi: 10.1016/s1359-6101(99)00034-9. Cytokine Growth Factor Rev. 2000. PMID: 10708958 Review.
Cited by
-
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.Pharmaceuticals (Basel). 2024 Apr 20;17(4):533. doi: 10.3390/ph17040533. Pharmaceuticals (Basel). 2024. PMID: 38675493 Free PMC article. Review.
-
TGF-β signaling in health, disease, and therapeutics.Signal Transduct Target Ther. 2024 Mar 22;9(1):61. doi: 10.1038/s41392-024-01764-w. Signal Transduct Target Ther. 2024. PMID: 38514615 Free PMC article. Review.
-
Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids.Int J Mol Sci. 2023 Jul 6;24(13):11178. doi: 10.3390/ijms241311178. Int J Mol Sci. 2023. PMID: 37446353 Free PMC article.
-
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.Signal Transduct Target Ther. 2021 Jun 10;6(1):218. doi: 10.1038/s41392-021-00641-0. Signal Transduct Target Ther. 2021. PMID: 34108441 Free PMC article. Review.
-
Human Marfan and Marfan-like Syndrome associated mutations lead to altered trafficking of the Type II TGFβ receptor in Caenorhabditis elegans.PLoS One. 2019 May 9;14(5):e0216628. doi: 10.1371/journal.pone.0216628. eCollection 2019. PLoS One. 2019. PMID: 31071172 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases